Evidence map›Paper›PMID 35560154›Full record

ArticleMolecular cancer research : MCR2022

Ceramide Kinase Inhibition Drives Ferroptosis and Sensitivity to Cisplatin in Mutant KRAS Lung Cancer by Dysregulating VDAC-Mediated Mitochondria Function.

Ngoc T Vu, Minjung Kim, Daniel J Stephenson, H Patrick MacKnight, Charles E Chalfant

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Mechanism of Ferroptosis and Its Role in Disease Development.International journal of biological sciences · 2025
    Review
  20. Sphingolipid metabolism and regulated cell death in malignant melanoma.Apoptosis : an international journal on programmed cell death · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Ngoc T VuDepartment of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, Florida.
Minjung KimDepartment of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, Florida.ORCID 0000-0002-5682-6640
Daniel J StephensonDepartment of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, Florida.
H Patrick MacKnightDepartment of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, Florida.ORCID 0000-0003-3232-6155
Charles E ChalfantDepartment of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, Florida.ORCID 0000-0002-5844-5235
University of South Florida · USIndustrial University of Ho Chi Minh City · VNUnited States Department of Veterans Affairs · US

Funding

The roles of ceramide and its derivatives in A. phagocytophilum pathogenesisR01AI139072 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI CHARLES E. CHALFANT, Jason A Carlyon · 2018 to 2026
$5.7M
The role and mechanistic regulation of cPLA2alpha in eicosanoid biosynthesis and wound healingR01GM137394 · NIGMS · UNIVERSITY OF VIRGINIA · PI CHALFANT, CHARLES E., KORDULA, TOMASZ K · 2021 to 2024
$1.9M
The role of ceramide kinase in mitophagyR01GM137578 · NIGMS · UNIVERSITY OF VIRGINIA · PI CHALFANT, CHARLES E. · 2020 to 2023
$1.3M
The role of RNA splicing in non-small cell lung cancerI01BX001792 · VA · VA VETERANS ADMINISTRATION HOSPITAL · PI CHALFANT, CHARLES E. · 2013 to 2024
–
BLRD Research Career Scientist Award ApplicationIK6BX004603 · VA · VA VETERANS ADMINISTRATION HOSPITAL · PI CHALFANT, CHARLES E. · 2019 to 2025
–
BLRD VA I01 BX001792BLRD VA IK6 BX004603NIAID NIH HHS R01 AI139072NIGMS NIH HHS R01 GM137394NIGMS NIH HHS R01 GM137578
6 · The paper itself

Abstract

Ceramide kinase (CERK) is the mammalian lipid kinase from which the bioactive sphingolipid, ceramide-1-phosphate (C1P), is derived. CERK has been implicated in several promalignant phenotypes with little known as to mechanistic underpinnings. In this study, the mechanism of how CERK inhibition decreases cell survival in mutant (Mut) KRAS non-small cell lung cancer (NSCLC), a major lung cancer subtype, was revealed. Specifically, NSCLC cells possessing a KRAS mutation were more responsive to inhibition, downregulation, and genetic ablation of CERK compared with those with wild-type (WT) KRAS regarding a reduction in cell survival. Inhibition of CERK induced ferroptosis in Mut KRAS NSCLC cells, which required elevating VDAC-regulated mitochondria membrane potential (MMP) and the generation of cellular reactive oxygen species (ROS). Importantly, through modulation of VDAC, CERK inhibition synergized with the first-line NSCLC treatment, cisplatin, in reducing cell survival and in vivo tumor growth. Further mechanistic studies indicated that CERK inhibition affected MMP and cell survival by limiting AKT activation and translocation to mitochondria, and thus, blocking VDAC phosphorylation and tubulin recruitment. IMPLICATIONS: Our findings depict how CERK inhibition may serve as a new key point in combination therapeutic strategy for NSCLC, specifically precision therapeutics targeting NSCLC possessing a KRAS mutation.

Indexed as

Carcinoma, Non-Small-Cell LungFerroptosisLung NeoplasmsAnimalsCeramidesCisplatinMammalsMitochondriaPhosphotransferases (Alcohol Group Acceptor)Proto-Oncogene Proteins p21(ras)ceramide kinaseCeramidesCisplatinPhosphotransferases (Alcohol Group Acceptor)Proto-Oncogene Proteins p21(ras)

Identifiers

PMID35560154
PMCPMC9444881
OpenAlexW4280502110

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.